产品名称	K-562人慢性髓原白血病细胞
货号	ZQ0424
产品介绍	K562细胞系来源于患有慢性骨髓性白血病的53岁女性患者的骨髓，Anderson等对其表面膜性质的研究表明，K-562是一株人类红白血病细胞。 K-562细胞株在自然杀伤分析中广泛作为高敏感的体外受体。 See Pross等将它用于NK细胞的体外详细检测，包括NK细胞活性的数学量化。 K-562母细胞是多能性，造血恶性细胞，它能自发分化成可识别的红血球祖细胞、粒性白细胞、单核细胞等。它是EBNA阴性的。是免疫学、肿瘤免疫学、免疫系统紊乱研究等多个领域的基础。人类K-562细胞广泛用于涉及免疫系统相互作用的研究，特别是与自然杀伤细胞(NK)等效应细胞的相互作用。这是由于它们的独特特性，例如表达可被NK细胞识别的特定抗原。探索NK细胞与K562等癌细胞系之间的相互作用，可以深入了解免疫防御机制。NK细胞对K562细胞的识别和反应能力随着特定标记物的存在而变化，这些标记物在整个K562细胞周期中波动。 K562细胞的特点是存在费城染色体，这是由于9号和22号染色体之间的易位，产生了BCR-ABL融合基因。这种融合基因不是正常的ABL转录本，而是一种突变形式，具有组成性活性，导致不受控制的细胞增殖。分析K562细胞中的ABL转录本有助于揭示白血病的分子动力学和免疫逃避策略。该细胞还是了解细胞周期，特别是分析细胞周期阶段和分布的关键。该分析对于评估ABL基因表达的影响和相关的ABL融合转录物的减少是必不可少的。此外，K562细胞在评估FGFR抑制剂的细胞毒性作用和表观遗传酶活性的分析中具有价值，突出了它们在阐明细胞信号通路和各种治疗剂的作用机制方面的重要性。 K562细胞的多功能性，从它在酶活性测定中的作用到它在自然杀伤(NK)细胞的免疫学研究中的应用，强调了它们在科学领域的广泛用途。这种适应性突出了它们在弥合基础研究和转化医学之间的差距方面的重要性，在推进对抗慢性骨髓性白血病方面发挥着至关重要的作用。 注意事项： a) 该细胞为悬浮细胞，根据培养经验以及客户的反馈，传代时使用【半换液法】对细胞状态较为有利，因此我库建议您使用【半换液法】进行传代。同时，您在收到细胞后，请不要通过离心的方式收集细胞，可以直接向培养瓶中添加等体积的新鲜培养液，然后将细胞吹打均匀后移入两个新的T25培养瓶中继续培养即可。 b) 该细胞对血清质量较为敏感，建议您使用大品牌优质血清进行培养。 c) 该细胞对细胞密度较为敏感，培养、传代时请注意保持细胞密度在合适的范围。细胞接种密度10万个/mL，维持密度10万-100万个/mL.
种属	人
性别/年龄	女/53岁
组织	骨；骨髓
疾病	慢性粒细胞白血病Cml
细胞类型	肿瘤细胞
形态学	成淋巴细胞
生长方式	悬浮
倍增时间	大约17~47小时
常规培养基和添加剂	IMDM培养基（品牌：中乔新舟 货号：ZQ-900）+10%胎牛血清（中乔新舟 货号：ZQ0500）+1%P/S（中乔新舟  货号：CSP006）
推荐含血清完全培养基货号	ZM0424
推荐无血清完全培养基货号	SFM0424
生物安全等级	BSL-1
STR位点信息	Amelogenin: X CSF1PO: 9,10 D13S317: 8 D16S539: 11,12 D5S818: 11,12 D7S820: 9,11 THO1: 9.3 TPOX: 8,9 vWA: 16
培养条件	95%空气，5%二氧化碳；37℃
抗原表达/受体表达	***
基因表达	***
保藏机构	ATCC; CCL-243 BCRC; 60007 BCRJ; 0126 CCLV; CCLV-RIE 0439 DSMZ; ACC-10 ECACC; 89121407
供应限制	仅供科研使用

货号	ZQ0424
发货规格	活细胞：T25培养瓶*1瓶或者1ml 冻存管*1支（细胞量约为5 x 10^5 cells/vial）二选一
发货形式	活细胞：常温运输；冻存管：干冰运输
储存温度	活细胞：培养箱；冻存管：液氮罐
产地	中国
供应限制	仅供科研使用

论文标题： Hinokiflavone induces apoptosis, cell cycle arrest and autophagy in chronic myeloid leukemia cells through MAPK/NF-κB signaling pathway
DOI： 10.1186/s12906-022-03580-7
发表时间： 2022-04-06
期刊： BMC Complementary and Alternative Medicine
影响因子： 3.659
货号： ZQ0424
产品名称： K562 cell line
原文链接： https://link.springer.com/article/10.1186/s12906-022-03580-7

论文标题： Engineering NK-92 Cell by Upregulating CXCR2 and IL-2 Via CRISPR-Cas9 Improves Its Antitumor Effects as Cellular Immunotherapy for Human Colon Cancer
DOI： 10.1089/jir.2021.0078
发表时间： 2021-12-15
期刊： JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
影响因子： 2.607
货号： ZQ0424
产品名称： K562 cells
原文链接： https://www.liebertpub.com/doi/abs/10.1089/jir.2021.0078

论文标题： PCAT18, as a novel differentially regulated long noncoding RNA in adult acute myeloid leukemia patients revealed by next-generation sequencing
DOI： 10.1111/ijlh.13305
发表时间： 2020-10-02
期刊： International Journal of Laboratory Hematology
影响因子： 2.141
货号： ZQ0424
产品名称： K-562 cells

原文链接： https://onlinelibrary.wiley.com/doi/abs/10.1111/ijlh.13305

PubMed=163658; DOI=10.1182/blood.V45.3.321.321
Lozzio C.B., Lozzio B.B.
Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome.
Blood 45:321-334(1975)

PubMed=924690; DOI=10.1002/ijc.2910200505
Kerbel R.S., Pross H.F., Leibovitz A.
Analysis of established human carcinoma cell lines for lymphoreticular-associated membrane receptors.
Int. J. Cancer 20:673-679(1977)

PubMed=367973; DOI=10.1002/ijc.2910230202
Andersson L.C., Nilsson K., Gahmberg C.G.
K562 -- a human erythroleukemic cell line.
Int. J. Cancer 23:143-147(1979)

PubMed=528075; DOI=10.1002/ijc.2910240422
Andersson L.C., Jokinen M., Gahmberg C.G., Klein E., Klein G., Nilsson K.
Presence of erythrocytic components in the K562 cell line.
Int. J. Cancer 24:514-514(1979)

PubMed=570644; DOI=10.1038/278364a0
Andersson L.C., Jokinen M., Gahmberg C.G.
Induction of erythroid differentiation in the human leukaemia cell line K562.
Nature 278:364-365(1979)

PubMed=6996765; DOI=10.1182/blood.V56.3.344.344
Koeffler H.P., Golde D.W.
Human myeloid leukemia cell lines: a review.
Blood 56:344-350(1980)

PubMed=7194480; DOI=10.3181/00379727-166-41106
Lozzio B.B., Lozzio C.B., Bamberger E.G., Feliu A.S.
A multipotential leukemia cell line (K-562) of human origin.
Proc. Soc. Exp. Biol. Med. 166:546-550(1981)

PubMed=6954533; DOI=10.1073/pnas.79.7.2194
Westin E.H., Gallo R.C., Arya S.K., Eva A., Souza L.M., Baluda M.A., Aaronson S.A., Wong-Staal F.
Differential expression of the amv gene in human hematopoietic cells.
Proc. Natl. Acad. Sci. U.S.A. 79:2194-2198(1982)

PubMed=6091813; DOI=10.1182/blood.V64.5.1059.1059
Palumbo A., Minowada J., Erikson J., Croce C.M., Rovera G.
Lineage infidelity of a human myelogenous leukemia cell line.
Blood 64:1059-1063(1984)

PubMed=6582512; DOI=10.1073/pnas.81.2.568
Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.
Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.
Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984)

PubMed=2985879; DOI=10.1016/0145-2126(85)90084-0
Drexler H.G., Gaedicke G., Minowada J.
Isoenzyme studies in human leukemia-lymphoma cell lines -- 1 carboxylic esterase.
Leuk. Res. 9:209-229(1985)

PubMed=3159941; DOI=10.1016/0145-2126(85)90134-1
Drexler H.G., Gaedicke G., Minowada J.
Isoenzyme studies in human leukemia-lymphoma cell lines -- III Beta-hexosaminidase (E.C. 3.2.1.30).
Leuk. Res. 9:549-559(1985)

PubMed=3856862; DOI=10.1073/pnas.82.6.1810
Konopka J.B., Watanabe S.M., Singer J.W., Collins S.J., Witte O.N.
Cell lines and clinical isolates derived from Ph1-positive chronic myelogenous leukemia patients express c-abl proteins with a common structural alteration.
Proc. Natl. Acad. Sci. U.S.A. 82:1810-1814(1985)

PubMed=3857109; DOI=10.1016/0165-4608(85)90101-3
Chen T.-R.
Modal karyotype of human leukemia cell line, K562 (ATCC CCL 243).
Cancer Genet. Cytogenet. 17:55-60(1985)

PubMed=3874327; DOI=10.1016/0145-2126(85)90133-x
Drexler H.G., Gaedicke G., Minowada J.
Isoenzyme studies in human leukemia-lymphoma cells lines -- II. Acid phosphatase.
Leuk. Res. 9:537-548(1985)

PubMed=3930277
Garson D., Dokhelar M.-C., Wakasugi H., Mishal Z., Tursz T.
HLA class-I and class-II antigen expression by human leukemic K562 cells and by Burkitt-K562 hybrids: modulation by differentiation inducers and interferon.
Exp. Hematol. 13:885-890(1985)

PubMed=3023859; DOI=10.1128/mcb.6.2.607-616.1986
Grosveld G., Verwoerd T., van Agthoven T., de Klein A., Ramachandran K.L., Heisterkamp N., Stam K., Groffen J.
The chronic myelocytic cell line K562 contains a breakpoint in bcr and produces a chimeric bcr/c-abl transcript.
Mol. Cell. Biol. 6:607-616(1986)

PubMed=2446768; DOI=10.1007/BF02797342
Walter H., Al-Romaihi F.A., Krob E.J., Seaman G.V.F.
Fractionation of K-562 cells on the basis of their surface properties by partitioning in two-polymer aqueous-phase systems.
Cell Biophys. 10:217-232(1987)

PubMed=3332852; DOI=10.1016/S0950-3536(87)80037-9
Keating A.
Ph positive CML cell lines.
Baillieres Clin. Haematol. 1:1021-1029(1987)

CLPUB00761

Carman M.D.
Altered and increased ribonucleotide reductase activity as a mechanism of resistance to hydroxyurea in a human myelogenous leukemia cell line.
Thesis PhD (1988), Yale University, United States

PubMed=2465826; DOI=10.1007/BF02918374
Walter H., Krob E.J., Al-Romaihi F.A., Johnson D., Lozzio C.B.
Detection of surface differences between closely related cell populations by partitioning. Cultured K-562 cell sublines.
Cell Biophys. 13:173-187(1988)

PubMed=3335022
Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.
Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.
Cancer Res. 48:589-601(1988)

PubMed=2568171
Yanovich S., Hall R.E., Gewirtz D.A.
Characterization of a K562 multidrug-resistant cell line.
Cancer Res. 49:4499-4503(1989)

PubMed=2140233; DOI=10.1111/j.1440-1827.1990.tb01549.x
Nakano A., Harada T., Morikawa S., Kato Y.
Expression of leukocyte common antigen (CD45) on various human leukemia/lymphoma cell lines.
Acta Pathol. Jpn. 40:107-115(1990)

PubMed=2041050; DOI=10.1093/jnci/83.11.757
Monks A., Scudiero D.A., Skehan P., Shoemaker R.H., Paull K.D., Vistica D.T., Hose C.D., Langley J., Cronise P., Vaigro-Wolff A., Gray-Goodrich M., Campbell H., Mayo J.G., Boyd M.R.
Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.
J. Natl. Cancer Inst. 83:757-766(1991)

CLPUB00447

Mulivor R.A., Suchy S.F.
1992/1993 catalog of cell lines. NIGMS human genetic mutant cell repository. 16th edition. October 1992.
(In) Institute for Medical Research (Camden, N.J.) NIH 92-2011; pp.1-918; National Institutes of Health; Bethesda (1992)

PubMed=8142256; DOI=10.1038/bjc.1994.131
Ritke M.K., Roberts D., Allan W.P., Raymond J., Bergoltz V.V., Yalowich J.C.
Altered stability of etoposide-induced topoisomerase II-DNA complexes in resistant human leukaemia K562 cells.
Br. J. Cancer 69:687-697(1994)

PubMed=8558913
Morita S., Tsuchiya S., Fujie H., Itano M., Ohashi Y., Minegishi M., Imaizumi M., Endo M., Takano N., Konno T.
Cell surface c-kit receptors in human leukemia cell lines and pediatric leukemia: selective preservation of c-kit expression on megakaryoblastic cell lines during adaptation to in vitro culture.
Leukemia 10:102-105(1996)

P

ubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D
Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T., Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M., Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.
Screening the p53 status of human cell lines using a yeast functional assay.
Mol. Carcinog. 19:243-253(1997)

P

ubMed=9510473; DOI=10.1111/j.1349-7006.1998.tb00476.x
Hosoya N., Hangaishi A., Ogawa S., Miyagawa K., Mitani K., Yazaki Y., Hirai H.
Frameshift mutations of the hMSH6 gene in human leukemia cell lines.
Jpn. J. Cancer Res. 89:33-39(1998)

PubMed=9738977; DOI=10.1111/j.1349-7006.1998.tb03275.x
Takizawa J., Suzuki R., Kuroda H., Utsunomiya A., Kagami Y., Joh T., Aizawa Y., Ueda R., Seto M.
Expression of the TCL1 gene at 14q32 in B-cell malignancies but not in adult T-cell leukemia.
Jpn. J. Cancer Res. 89:712-718(1998)

PubMed=10071072; DOI=10.1016/S0145-2126(98)00171-4
Drexler H.G., MacLeod R.A.F., Uphoff C.C.
Leukemia cell lines: in vitro models for the study of Philadelphia chromosome-positive leukemia.
Leuk. Res. 23:207-215(1999)

PubMed=10576511; DOI=10.1016/s0145-2126(99)00131-9
Uphoff C.C., Habig S., Fombonne S., Matsuo Y., Drexler H.G.
ABL-BCR expression in BCR-ABL-positive human leukemia cell lines.
Leuk. Res. 23:1055-1060(1999)

PubMed=10700174; DOI=10.1038/73432
Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T., Iyer V.R., Jeffrey S.S., van de Rijn M., Waltham M.C., Pergamenschikov A., Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N., Botstein D., Brown P.O.
Systematic variation in gene expression patterns in human cancer cell lines.
Nat. Genet. 24:227-235(2000)

PubMed=10739008; DOI=10.1016/S0145-2126(99)00182-4
Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.
Frequent microsatellite instability and BAX mutations in T cell acute lymphoblastic leukemia cell lines.
Leuk. Res. 24:255-262(2000)

PubMed=11021758; DOI=10.1038/sj.leu.2401891
Majka M., Rozmyslowicz T., Honczarenko M., Ratajczak J., Wasik M.A., Gaulton G.N., Ratajczak M.Z.
Biological significance of the expression of HIV-related chemokine coreceptors (CCR5 and CXCR4) and their ligands by human hematopoietic cell lines.
Leukemia 14:1821-1832(2000)

DOI=10.1016/B978-0-12-221970-2.50457-5
Drexler H.G.
The leukemia-lymphoma cell line factsbook.
(In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001)

PubMed=11226526; DOI=10.1016/S0145-2126(00)00121-1
Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.
Corrigendum to: Frequent microsatellite instability and BAX mutations in T cell acute lymphoblastic leukemia cell lines Leukemia Research 24 (2000),255-262.
Leuk. Res. 25:275-278(2001)

PubMed=11248328; DOI=10.1016/S0145-2126(00)00125-9
Naumann S., Reutzel D., Speicher M.R., Decker H.-J.
Complete karyotype characterization of the K562 cell line by combined application of G-banding, multiplex-fluorescence in situ hybridization, fluorescence in situ hybridization, and comparative genomic hybridization.
Leuk. Res. 25:313-322(2001)

PubMed=11416159; DOI=10.1073/pnas.121616198
Masters J.R.W., Thomson J.A., Daly-Burns B., Reid Y.A., Dirks W.G., Packer P., Toji L.H., Ohno T., Tanabe H., Arlett C.F., Kelland L.R., Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.
Short tandem repeat profiling provides an international reference standard for human cell lines.
Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001)

PubMed=12506034; DOI=10.1182/blood-2002-06-1770
Uno K., Inukai T., Kayagaki N., Goi K., Sato H., Nemoto A., Takahashi K., Kagami K., Yamaguchi N., Yagita H., Okumura K., Koyama-Okazaki T., Suzuki T., Sugita K., Nakazawa S.
TNF-related apoptosis-inducing ligand (TRAIL) frequently induces apoptosis in Philadelphia chromosome-positive leukemia cells.
Blood 101:3658-3667(2003)

PubMed=12859996; DOI=10.1016/S0145-2126(03)00072-9
Day N.E., Ugai H., Yokoyama K.K., Ichiki A.T.
K-562 cells lack MHC class II expression due to an alternatively spliced CIITA transcript with a truncated coding region.
Leuk. Res. 27:1027-1038(2003)

PubMed=14642717; DOI=10.1016/j.forsciint.2003.09.002
Szibor R., Edelmann J., Hering S., Plate I., Wittig H., Roewer L., Wiegand P., Cali F., Romano V., Michael M.
Cell line DNA typing in forensic genetics -- the necessity of reliable standards.
Forensic Sci. Int. 138:37-43(2003)

PubMed=15637111; DOI=10.1096/fj.04-3062fje
Parson W., Kirchebner R., Muhlmann R., Renner K., Kofler A., Schmidt S., Kofler R.
Cancer cell line identification by short tandem repeat profiling: power and limitations.
FASEB J. 19:434-436(2005)

PubMed=15748285; DOI=10.1186/1479-5876-3-11
Adams S., Robbins F.-M., Chen D., Wagage D., Holbeck S.L., Morse H.C. III, Stroncek D., Marincola F.M.
HLA class I and II genotype of the NCI-60 cell lines.
J. Transl. Med. 3:11.1-11.8(2005)

PubMed=15843827; DOI=10.1038/sj.leu.2403749
Andersson A., Eden P., Lindgren D., Nilsson J., Lassen C., Heldrup J., Fontes M., Borg A., Mitelman F., Johansson B., Hoglund M., Fioretos T.
Gene expression profiling of leukemic cell lines reveals conserved molecular signatures among subtypes with specific genetic aberrations.
Leukemia 19:1042-1050(2005)

PubMed=16408098; DOI=10.1038/sj.leu.2404081
Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.
JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders.
Leukemia 20:471-476(2006)

PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433
Ikediobi O.N., Davies H., Bignell G.R., Edkins S., Stevens C., O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L., Buck G., Butler A.P., Clements J., Cole J., Dicks E., Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C., Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A., Mironenko T., Parker A., Perry J., Raine K.M., Richardson D., Shepherd R., Small A., Smith R., Solomon H., Stephens P.J., Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.
Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.
Mol. Cancer Ther. 5:2606-2612(2006)

PubMed=18277095; DOI=10.4161/cbt.7.5.5712
Berglind H., Pawitan Y., Kato S., Ishioka C., Soussi T.
Analysis of p53 mutation status in human cancer cell lines: a paradigm for cell line cross-contamination.
Cancer Biol. Ther. 7:699-708(2008)

PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921
Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y., Chanock S.J., Weinstein J.N.
DNA fingerprinting of the NCI-60 cell line panel.
Mol. Cancer Ther. 8:713-724(2009)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=20809971; DOI=10.1186/1755-8166-3-15
Virgili A., Nacheva E.
Genomic amplification of BCR/ABL1 and a region downstream of ABL1 in chronic myeloid leukaemia: a FISH mapping study of CML patients and cell lines.
Mol. Cytogenet. 3:15.1-15.12(2010)

PubMed=21269460; DOI=10.1186/1752-0509-5-17
Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Burckstummer T., Bennett K.L., Superti-Furga G., Colinge J.
Initial characterization of the human central proteome.
BMC Syst. Biol. 5:17.1-17.13(2011)

PubMed=21552520; DOI=10.1371/journal.pone.0019169
Gu T.-L., Nardone J., Wang Y., Loriaux M., Villen J., Beausoleil S.A., Tucker M., Kornhauser J.M., Ren J.-M., MacNeill J., Gygi S.P., Druker B.J., Heinrich M.C., Rush J., Polakiewicz R.D.
Survey of activated FLT3 signaling in leukemia.
PLoS ONE 6:E19169-E19169(2011)

PubMed=22068913; DOI=10.1073/pnas.1111840108
Gillet J.-P., Calcagno A.M., Varma S., Marino M., Green L.J., Vora M.I., Patel C., Orina J.N., Eliseeva T.A., Singal V., Padmanabhan R., Davidson B., Ganapathi R., Sood A.K., Rueda B.R., Ambudkar S.V., Gottesman M.M.
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance.
Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011)

PubMed=22278370; DOI=10.1074/mcp.M111.014050
Geiger T., Wehner A., Schaab C., Cox J., Mann M.
Comparative proteomic analysis of eleven common cell lines reveals ubiquitous but varying expression of most proteins.
Mol. Cell. Proteomics 11:M111.014050-M111.014050(2012)

PubMed=22347499; DOI=10.1371/journal.pone.0031628
Ruan X.-Y., Kocher J.-P.A., Pommier Y., Liu H.-F., Reinhold W.C.
Mass homozygotes accumulation in the NCI-60 cancer cell lines as compared to HapMap trios, and relation to fragile site location.
PLoS ONE 7:E31628-E31628(2012)

PubMed=22384151; DOI=10.1371/journal.pone.0032096
Lee J.-S., Kim Y.K., Kim H.J., Hajar S., Tan Y.L., Kang N.-Y., Ng S.H., Yoon C.N., Chang Y.-T.
Identification of cancer cell-line origins using fluorescence image-based phenomic screening.
PLoS ONE 7:E32096-E32096(2012)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=22628656; DOI=10.1126/science.1218595
Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L., Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.
Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation.
Science 336:1040-1044(2012)

PubMed=23325432; DOI=10.1101/gr.147942.112
Varley K.E., Gertz J., Bowling K.M., Parker S.L., Reddy T.E., Pauli-Behn F., Cross M.K., Williams B.A., Stamatoyannopoulos J.A., Crawford G.E., Absher D.M., Wold B.J., Myers R.M.
Dynamic DNA methylation across diverse human cell lines and tissues.
Genome Res. 23:555-567(2013)